Amgen, Novartis Trade Rights For Migraine, Alzheimer's Drugs
This article was originally published in Scrip
Executive Summary
Amgen traded certain ex-US rights to its Phase III calcitonin gene-related peptide (CGRP) inhibitor for migraine headaches to acquire shared global rights to Novartis's early-stage candidate for Alzheimer's disease, raising an important question: Who is getting the better deal?
You may also be interested in...
Novartis/Amgen End CNP520 Studies, Leaving Eisai/Biogen With Last BACE Inhibitor In The Clinic
An interim look at two Phase II/III trials showed the drug worsened cognition in people at high risk of developing Alzheimer's disease. This is the 16th failure of a BACE-targeting therapy.
As Amgen Looks To Aimovig's Launch, It May Learn From Repatha's Past
Amgen started 2018 off on solid footing with a 2% jump in Q1 revenue to $5.55bn versus consensus estimates of $5.4bn, but new drugs like the CGRP inhibitor Aimovig are needed to keep the momentum going and supplement declining sales for key products.
Amgen, Novartis May Screen 30,000 Patients To Find 2,000 For Alzheimer's Trial
A new trial for CNP520 will see if the Amgen/Novartis BACE1 inhibitor can prevent, stop or slow Alzheimer's disease progression in pre-symptomatic patients, but recruiting enough patients with the APOE4 gene will require a massive screening effort.